Nightingale Health

2.68

EUR

-0.74 %

4,567 following

HEALTH

First North Finland

Medical Equipment & Services

Health Care

Overview

Financials & Estimates

-0.74%

-4.96%

-6.94%

-5.63%

-20.94%

+153.31%

+29.09%

-

-47.96%

Nightingale Health operates in medical technology. The company specializes in the development of medical devices. The product portfolio is broad and includes platforms and services in blood tests that are used for disease prevention purposes. In addition to the main business, service and associated ancillary services are also offered. The business is run globally with the largest presence in Europe.

Market cap

163.29M EUR

Turnover

91.43K EUR

P/E (adj.) (25e)

-10

EV/EBIT (adj.) (25e)

-6.28

P/B (25e)

2.35

EV/S (25e)

20.9

Dividend yield-% (25e)

-

Coverage

Recommendation

Accumulate

Target price

2.90 EUR

Updated

07.03.2025

Antti Luiro

Head of Nordic ER Development, Analyst

Latest research

Latest analysis report

Released: 07.03.2025

Latest extensive report

Released: 05.06.2023

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Risk

Business risk

Valuation risk

Low

High

ShowingAll content types

Nightingale H1'FY25: Blood draws again

Research3/7/2025, 9:45 AM by

Nightingale H1'FY25: Blood draws again

Nightingale is just launching the commercial phases with its second and third healthcare partners. The company's comments on the sales pipeline are also promising, and we believe it will announce at least one significant partnership during the current year.

Nightingale Health

Nightingale, Webcast, Q2'25

Webcast3/6/2025, 12:00 PM

Nightingale, Webcast, Q2'25

Nightingale Health

Regulatory press release3/6/2025, 7:00 AM

Nightingale Health's half-year report: International expansion continues in Southeast Asia and the United States

Nightingale Health

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Nightingale H1’FY25 preview: Maturing the next wave of pilots

Analyst Comment3/5/2025, 7:38 AM by

Nightingale H1’FY25 preview: Maturing the next wave of pilots

Driven by the Terveystalo partnership, which was successfully launched at the beginning of 2024, revenue is on an upward trend compared to the previous year.

Nightingale Health

Press release2/28/2025, 10:35 AM

Nightingale Health to publish half-year report for July - December 2024 on 6 March 2025

Nightingale Health

Press release2/27/2025, 12:15 PM

Nightingale Health announces the development of innovative LLM based tool to empower anyone to take informed decisions to lower disease risks

Nightingale Health

Analyst Comment2/10/2025, 7:42 AM by

Nightingale's path to regulatory approval in the US is becoming clearer and progressing

As promised, Nightingale provided further information on plans to obtain regulatory approvals in the US on Friday.

Nightingale Health

Press release2/7/2025, 12:15 PM

Nightingale Health announces its updated regulatory plan in the United States

Nightingale Health

Analyst Comment1/27/2025, 10:47 AM by

Nightingale Health enters Middle East collaboration

Nightingale has signed a pilot agreement and letter of intent with Enigma Genomics to use the company's Remote Health Check in a full-scale commercial operation for Enigma's clients in Saudi Arabia and the wider MENA region.

Nightingale Health

Press release1/27/2025, 7:00 AM

Nightingale Health and Enigma Genomics enter into collaboration to sell the Nightingale Remote Health Check in the MENA region

Nightingale Health

Analyst Comment1/24/2025, 7:46 AM by

Nightingale Health published new disease risk assessments

Nightingale announced that it has published two new disease risk assessments for its Health Check service: fatty liver disease and stroke.

Nightingale Health

Press release1/23/2025, 9:00 AM

Nightingale Health announces the performance metrics of its latest generation disease risk assessments to be rolled out in Singapore and the United States

Nightingale Health

Regulatory press release12/23/2024, 12:00 PM

Conversion of Nightingale Health Plc's EMP shares to Series B shares

Nightingale Health

Regulatory press release12/20/2024, 3:35 PM

Nightingale Health Plc - Managers' Transactions - Olli Karhi

Nightingale Health

Regulatory press release12/18/2024, 7:35 PM

Nightingale Health Plc appoints Lago Kapital as liquidity provider

Nightingale Health

Regulatory press release12/13/2024, 1:50 PM

Nightingale Health Plc: Subscription of Series B shares with option rights

Nightingale Health

Press release12/4/2024, 8:00 AM

Study published in Nature Communications: Nightingale Health outperforms genetic testing in chronic disease risk detection and makes the promise of preventative health a reality

Nightingale Health

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia Technologies BBS-Bioactive Bone Substitutes Bioretec Biohit Faron Pharmaceuticals Modulight Nexstim Orion Bittium Detection Technology Optomed Revenio Group Nightingale Health Herantis Pharma Nanoform Finland

Analyst Comment11/29/2024, 11:06 AM by

Nightingale opens Singapore laboratory

According to the release, the opening of the laboratory will be celebrated on Monday, December 2, and the company expects the first healthcare samples to arrive at the laboratory during Q1/2025.

Nightingale Health

Press release11/29/2024, 9:30 AM

Nightingale Health announces opening of its Singapore laboratory

Nightingale Health

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.